Xenon Pharmaceuticals Inc’s recently made public that its Director GAROFALO ELIZABETH A. unloaded Company’s shares for reported $95583.0 on Mar 08 ’24. In the deal valued at $45.69 per share,2,092 shares were sold. As a result of this transaction, GAROFALO ELIZABETH A. now holds 0 shares worth roughly $0.0.
Then, GANNON STEVEN sold 13,000 shares, generating $601,615 in total proceeds. Upon selling the shares at $46.28, the Director now owns 2,000 shares.
Before that, ROBIN SHERRINGTON sold 7,137 shares. Xenon Pharmaceuticals Inc shares valued at $330,290 were divested by the EVP, Strategy & Innovation at a price of $46.28 per share. As a result of the transaction, ROBIN SHERRINGTON now holds 8,398 shares, worth roughly $0.36 million.
Citigroup initiated its Xenon Pharmaceuticals Inc [XENE] rating to a Buy in a research note published on January 04, 2024; the price target was $62. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Cantor Fitzgerald started covering the stock on April 25, 2023. It rated XENE as “an Overweight”.
Price Performance Review of XENE
On Monday, Xenon Pharmaceuticals Inc [NASDAQ:XENE] saw its stock jump 5.51% to $42.73. Over the last five days, the stock has gained 6.80%. Xenon Pharmaceuticals Inc shares have fallen nearly -7.23% since the year began. Nevertheless, the stocks have risen 8.51% over the past one year. While a 52-week high of $50.99 was reached on 03/01/24, a 52-week low of $27.99 was recorded on 04/25/24. SMA at 50 days reached $43.95, while 200 days put it at $39.75. A total of 0.63 million shares were traded, compared to the trading of 0.33 million shares in the previous session.
Levels Of Support And Resistance For XENE Stock
The 24-hour chart illustrates a support level at 41.28, which if violated will result in even more drops to 39.83. On the upside, there is a resistance level at 43.50. A further resistance level may holdings at 44.27. The Relative Strength Index (RSI) on the 14-day chart is 54.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 12.81%. Stochastics %K at 50.79% indicates the stock is a holding.
The most recent change occurred on December 14, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
